AIM ImmunoTech secured European and U.K. patent protection for Ampligen (rintatolimod) for Long COVID, with exclusivity expected to run through June 2041. The development strengthens IP durability for its Long COVID program and should be supportive of longer-term commercial optionality.
AIM ImmunoTech secured European and U.K. patent protection for Ampligen (rintatolimod) for Long COVID, with exclusivity expected to run through June 2041. The development strengthens IP durability for its Long COVID program and should be supportive of longer-term commercial optionality.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
